Decision-Making Biomarkers in the Treatment of Hepatocellular Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 47
Special Issue Editors
Interests: hepatocellular carcinoma; alcohol-associated liver disease; metabolic dysfunction-associated steatotic liver disease
Interests: hepatocellular carcinoma; neoadjuvant therapy; conversion therapy; surgical treatment
Special Issue Information
Dear Colleagues,
In recent years, significant progress has been made in the treatment of hepatocellular carcinoma (HCC). With the introduction of various therapeutic options, selecting the optimal treatment strategy for each patient has become increasingly important. In drug therapy, the advent of combination immunotherapy has transformed the treatment paradigm for advanced HCC, steadily improving patient prognosis. However, new challenges, such as immune-related adverse events, have also emerged. In surgical treatment, “conversion therapy” has become a viable option for patients with advanced HCC who respond to drug therapy. Additionally, the concept of “borderline resectable” disease has been proposed. However, there is still insufficient evidence to determine whether conversion surgery improves long-term prognosis. This Special Issue aims to present the latest research findings, from basic science to clinical applications. Topics include the prediction of disease progression using research biomarkers, the evaluation of relapse risk, and prognostic biomarkers, alongside established clinical tools such as blood biochemistry and imaging.
Dr. Norihiro Imai
Dr. Dongming Liu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- borderline resectable
- conversion therapy
- neoadjuvant therapy
- immunotherapy
- immune-related adverse event
- molecular-targeted agent
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
